Literature DB >> 19280108

Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas.

Kazuyuki Nagai1, Ryuichiro Doi, Tatsuo Ito, Atsushi Kida, Masayuki Koizumi, Toshihiko Masui, Yoshiya Kawaguchi, Kohei Ogawa, Shinji Uemoto.   

Abstract

BACKGROUND: The international consensus guidelines (the guidelines) for management of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas recommend surgical resection of branch duct IPMNs with any of the following features: cyst size >30 mm, mural nodules, main pancreatic duct diameter >6 mm, positive cytology, and symptoms. The aim of this study was to evaluate the usefulness of these guidelines for resection of branch duct IPMNs.
METHODS: We reviewed 84 consecutive patients with branch duct IPMNs who underwent surgical resection at our hospital between January 1984 and December 2007.
RESULTS: Sixty-nine patients had indications for resection according to the guidelines. Malignant IPMNs had significantly larger cysts than benign tumors (P = 0.026). Patients with malignant IPMNs had significantly more indications for resection than those with benign IPMNs (2.6 +/- 1.0 vs. 1.7 +/- 0.9, P < 0.001), and 36 of the 37 patients with malignant IPMNs had indications. The sensitivity of the guidelines for predicting malignancy was 97.3%. One of 15 patients without indications had malignancy, and the specificity was low (29.8%).
CONCLUSIONS: The guidelines show a high sensitivity for predicting malignancy of branch duct IPMNs, but the specificity is low. The cyst size and the total number of indications in each patient should be taken into account when predicting the risk of malignancy for branch duct IPMNs.

Entities:  

Mesh:

Year:  2009        PMID: 19280108     DOI: 10.1007/s00534-009-0068-8

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  34 in total

Review 1.  Novel Biomarkers for Pancreatic Cysts.

Authors:  Harkirat Singh; Kevin McGrath; Aatur D Singhi
Journal:  Dig Dis Sci       Date:  2017-02-14       Impact factor: 3.199

2.  Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.

Authors:  Marc A Attiyeh; Carlos Fernández-Del Castillo; Mohammad Al Efishat; Anne A Eaton; Mithat Gönen; Ruqayyah Batts; Ilaria Pergolini; Neda Rezaee; Keith D Lillemoe; Cristina R Ferrone; Mari Mino-Kenudson; Matthew J Weiss; John L Cameron; Ralph H Hruban; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; William R Jarnagin; Christopher L Wolfgang; Peter J Allen
Journal:  Ann Surg       Date:  2018-01       Impact factor: 12.969

3.  Determining the natural history of pancreatic cystic neoplasms: a Manitoban cohort study.

Authors:  Jon Broughton; Jeremy Lipschitz; Michael Cantor; Dana Moffatt; Ahmed Abdoh; Andrew McKay
Journal:  HPB (Oxford)       Date:  2016-01-29       Impact factor: 3.647

4.  Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct.

Authors:  Mee Joo Kang; Jin-Young Jang; Selyeong Lee; Taesung Park; Seung Yeoun Lee; Sun-Whe Kim
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

Review 5.  Cystic pancreatic lesions: From increased diagnosis rate to new dilemmas.

Authors:  S Nougaret; L Mannelli; M-A Pierredon; V Schembri; B Guiu
Journal:  Diagn Interv Imaging       Date:  2016-11-11       Impact factor: 4.026

Review 6.  Pancreatic cystic lesions: when to watch, when to operate, and when to ignore.

Authors:  Brian G Turner; William R Brugge
Journal:  Curr Gastroenterol Rep       Date:  2010-04

Review 7.  Pancreatic Cysts and Guidelines.

Authors:  James J Farrell
Journal:  Dig Dis Sci       Date:  2017-05-20       Impact factor: 3.199

8.  Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.

Authors:  Thula Cannon Walter; Ingo G Steffen; Lars H Stelter; Martin H Maurer; Marcus Bahra; Wladimir Faber; Fritz Klein; Hendrik Bläker; Bernd Hamm; Timm Denecke; Christian Grieser
Journal:  Eur Radiol       Date:  2014-11-30       Impact factor: 5.315

9.  Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms.

Authors:  Dirk Bausch; Mari Mino-Kenudson; Carlos Fernández-Del Castillo; Andrew L Warshaw; Kimberly A Kelly; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2009-09-17       Impact factor: 3.452

Review 10.  Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Yoshiyuki Nakajima; Takatsugu Yamada; Masayuki Sho
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.